Prognosis of patients with advanced hodgkin's disease

To determine whether a high risk group could be identified within a group of patients with advanced stage Hodgkin's disease (HD), the authors applied several prognostic models to patients treated according to the H89 protocol.

[1]  J. Radford,et al.  Prognostic factors for disease progression in advanced Hodgkin's disease: an analysis of patients aged under 60 years showing no progression in the first 6 months after starting primary chemotherapy. , 1997, British Journal of Cancer.

[2]  V. Diehl,et al.  Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  F. Berger,et al.  The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  V. Diehl,et al.  Bone marrow involvement in Hodgkin's disease: an analysis of 135 consecutive cases. German Hodgkin's Lymphoma Study Group. , 1995, Journal of Clinical Oncology.

[5]  V. Diehl,et al.  Is there a rationale for high-dose chemotherapy as first line treatment of advanced Hodgkin's disease? German Hodgkin's Lymphoma Study Group (GHSG). , 1995, Leukemia & lymphoma.

[6]  T. Miller,et al.  Low-Dose Involved Field Radiation after Chemotherapy in Advanced Hodgkin Disease: A Southwest Oncology Group Randomized Study , 1994, Annals of Internal Medicine.

[7]  A. Hagenbeek,et al.  A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  P. Gobbi,et al.  Estimate of expected survival at diagnosis in Hodgkin's disease: a means of weighting prognostic factors and a tool for treatment choice and clinical research. A report from the International Database on Hodgkin's Disease (IDHD). , 1994, Haematologica.

[9]  J. S. San Miguel,et al.  Serum lactate dehydrogenase level as a prognostic factor in Hodgkin's disease. , 1993, British Journal of Cancer.

[10]  C. Begg,et al.  Age and Hodgkin's disease: the impact of competing risks and possibly salvage therapy on long term survival: an E.C.O.G. study. , 1993, Leukemia research.

[11]  K. Propert,et al.  Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. , 1992, The New England journal of medicine.

[12]  L. Israels,et al.  Combined modality therapy of Hodgkin's disease: 10-year results of National Cancer Institute of Canada Clinical Trials Group multicenter clinical trial. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  A. Bacigalupo,et al.  Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin's disease in first complete remission after MOPP/ABVD protocol. , 1991, Bone marrow transplantation.

[14]  P. Donnan,et al.  A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party. , 1991, European journal of cancer.

[15]  B. Clarkson,et al.  Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  N. Nissen,et al.  Prognostic factors in Hodgkin's disease stage IV , 1988, European journal of haematology.

[17]  T. Lister,et al.  Prognostic factors for survival in stage IIIB and IV Hodgkin's disease: a multivariate analysis comparing two specialist treatment centres. , 1988, British Journal of Cancer.

[18]  J. Connors,et al.  An update on the Vancouver experience in the management of advanced Hodgkin's disease treated with the MOPP/ABV Hybrid program. , 1988, Seminars in hematology.

[19]  E. Jaffe,et al.  Twenty years of MOPP therapy for Hodgkin's disease. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  A. Santoro,et al.  Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results. , 1986, Annals of internal medicine.

[21]  L. Specht,et al.  Therapeutic implications of mediastinal involvement in advanced Hodgkin's disease. , 2009, Scandinavian journal of haematology.

[22]  D. Deakin,et al.  The prognostic significance of mediastinal bulk in patients with stage IA-IVB Hodgkin's disease: a report from the Manchester Lymphoma Group. , 1985, Clinical radiology.

[23]  G. Rosner,et al.  BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study. , 1984, Annals of internal medicine.

[24]  K. Maclennan,et al.  The pretreatment peripheral blood lymphocyte count in 1100 patients with Hodgkin's disease: the prognostic significance and the relationship to the presence of systemic symptoms. , 1981, Clinical oncology.

[25]  C. Bloomfield,et al.  Prognostic significance of mediastinal involvement in Hodgkin's disease treated with curative radiotherapy , 1980, Cancer.

[26]  J. Knowelden,et al.  Relationship of the Pre‐treatment Peripheral Lymphocyte Count to Histology in Hodgkin's Disease , 1973, British journal of haematology.

[27]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[28]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .